Quick facts

• Medicine: Pentasa (mesalazine)
• What it treats: Inflammatory bowel disease, mainly ulcerative colitis
• How it works: Helps reduce inflammation in the bowel lining
• Common formulations: Usually oral granules or modified-release tablets (availability may vary)
• Key point: Take regularly as directed, even when you feel well

Basic product information

Formulations and strengths can vary. Always check the product packaging and the instructions provided with your specific pack. If you are unsure which formulation you have, ask your pharmacist.

How Pentasa works (mechanism of action)

Mesalazine targets inflammation within the intestinal lining. While the exact mechanism in ulcerative colitis is complex, it mainly acts locally in the gut to reduce the release of inflammatory substances and to limit immune-driven damage.

• Local anti-inflammatory action: helps calm the inflammatory process in the colon/large bowel.
• Reduction of inflammatory mediators: may decrease substances involved in inflammation.
• Antioxidant effects: can help counter oxidative stress in inflamed tissue.
• Gentle immunomodulation: supports long-term control when taken consistently.

Pentasa is not a steroid. It is intended for controlling symptoms and helping maintain remission in the appropriate patients.

Pharmacokinetics — what the body does to mesalazine

Pharmacokinetics describe how the body absorbs, distributes, metabolises, and eliminates a medicine. With mesalazine, a key goal is local delivery to the gut wall.

Absorption and release

• Modified release delivery: Pentasa formulations are designed to release mesalazine gradually through the bowel.
• Local effect: a significant portion acts in the intestinal lining rather than as a whole-body drug.

Metabolism

• Mesalazine is partly metabolised in the intestinal wall and liver to acetyl-5‑ASA (N‑acetylated metabolite).

Elimination

• The medicine and metabolites are primarily eliminated via the kidneys (urine) and to some extent through the gut.
• Kidney function can therefore matter when taking mesalazine.

Individual absorption can vary depending on bowel inflammation, stool transit time, and formulation type. That is one reason clinicians may adjust dosing or switch formulations.

Typical uses in the UK

In the United Kingdom, mesalazine medicines such as Pentasa are widely used for inflammatory bowel disease (IBD). The most common indication is ulcerative colitis.

Common indications

• Ulcerative colitis (UC): treatment of mild to moderate attacks and/or maintaining remission.
• Inflammation of the colon where mesalazine is appropriate based on disease extent and severity.

In some cases, mesalazine may also be considered for other inflammatory bowel conditions under specialist guidance. Your pharmacist or prescriber can confirm the intended reason for your specific pack.

When to take Pentasa (timing and routine)

Consistency is important. Pentasa works best when it is taken regularly and as directed, even if symptoms improve.

Typical timing

• Once or multiple times daily: depending on your dose and the formulation.
• Same times each day: helps maintain steady drug levels in the gut.
• Don’t skip doses: missing doses may reduce effectiveness.

How to take

• Follow your pack instructions carefully.
• If you use granules, your product instructions will explain whether to swallow whole or take with a suitable food/vehicle.
• Do not crush or chew modified release formulations unless the leaflet for your specific product says it is safe.

If you miss a dose, take it when you remember unless it is close to the next dose. In that case, skip the missed dose and continue as normal. Do not take a double dose to make up for a missed one.

Food interactions (and what to eat/drink)

Mesalazine is designed for gut-local action. In general, you can usually take it with or without food, but your exact product guidance matters.

• Take with food if it upsets your stomach: some people find it easier to tolerate with a meal.
• Avoid making sudden dietary changes that significantly affect bowel transit time. If symptoms worsen after a major change, discuss it with your clinician.
• Hydration: maintain adequate fluid intake, especially during an active flare.

There are no well-known “forbidden” foods in most patients, but personal tolerance can vary. If you notice a pattern (for example, symptoms worsen after certain meals), keep a note to discuss with your healthcare team.

Alcohol and medicine interactions

Alcohol can affect the digestive system and may worsen symptoms in some people with IBD. While there isn’t a single universal rule for all patients, moderation is generally sensible.

Alcohol

• Moderate intake: may be tolerated by some patients in remission.
• During a flare: it may increase discomfort and should be avoided if it worsens symptoms.
• If you have liver or kidney problems: discuss alcohol and overall medication safety with your clinician.

Other medicines that may interact

Mesalazine can interact with other medicines in certain circumstances. The most important considerations include:

• Kidney-impacting medicines: because mesalazine metabolites are eliminated through the kidneys, use caution with medicines that can affect renal function.
• Warfarin (a blood thinner): some interactions may occur; your anticoagulation should be monitored if relevant.
• Azathioprine/mercaptopurine (immunosuppressants): combination therapy is sometimes used in IBD, but monitoring is important and should be coordinated by specialists.
• Non-steroidal anti-inflammatory drugs (NSAIDs): in some IBD patients, NSAIDs may worsen symptoms. Ask a pharmacist if you’re considering ibuprofen/naproxen or similar.

Always tell your pharmacist or prescriber about all medicines and supplements you take, including over-the-counter products.

Dosing — general guidance and what to expect

Doses vary depending on the condition being treated, disease severity, extent of inflammation, and the specific Pentasa formulation. Always use your prescribed/labelled dosing instructions.

Common dosing approach (high-level)

• For active disease: dosing is often higher to achieve symptom control.
• For maintenance: lower dosing may be used to help prevent relapse.
• Divided doses: many regimens split the daily dose across the day for better tolerability.

If you have ulcerative colitis, your clinician may adjust the dose based on response. Some people improve within weeks, while others may take longer. If your symptoms do not improve as expected, contact your healthcare team rather than stopping the medicine.

Practical tips to stay on track

• Use a daily routine: link doses to meals or bedtime as advised.
• Phone reminders: consider setting an alarm if you’re prone to forgetting.
• Keep a medication log: helpful during flares or dose adjustments.

Safety profile — who should be careful

Like all medicines, Pentasa can cause side effects. Most people tolerate it well, but important risks should be recognised early. This section summarises common and serious concerns; always refer to the official patient information leaflet for your specific product.

Common side effects

• Headache
• Nausea or stomach discomfort
• Flatulence (wind)
• Abdominal pain or diarrhoea may occur (sometimes making it hard to distinguish from the disease)
• Rash or itching in some patients

Serious but less common risks

• Allergic reactions: seek urgent advice if you develop swelling of the face/lips, breathing difficulty, or widespread rash.
• Kidney problems: mesalazine can rarely affect kidney function. Symptoms may include reduced urine output, swelling, or unusual tiredness.
• Blood disorders: rare changes in blood counts can occur; this may be picked up on blood tests.
• Severe inflammation in the bowel or intolerance: some people experience worsening symptoms that require assessment.

Monitoring in the UK

Patients taking mesalazine commonly undergo periodic monitoring, which may include:

• Blood tests (for inflammation markers and blood counts, depending on clinical plan)
• Kidney function tests (e.g., creatinine/eGFR)
• Urine tests in some circumstances

If you have pre-existing kidney disease, your clinician may monitor more frequently. Never ignore new or worsening symptoms.

Practical use tips (to get the best results)

• Don’t stop suddenly: stopping mesalazine without medical advice can increase the risk of relapse.
• Take exactly as directed: different mesalazine products are not always interchangeable dose-for-dose.
• Support during flares: keep a symptom diary (stool frequency, blood, urgency, pain). It helps your clinician judge response and decide on next steps.
• Watch your kidneys: if you’re dehydrated (vomiting, diarrhoea, poor intake), speak to a clinician, because dehydration can affect kidney function.
• Keep appointments for monitoring: blood and urine tests are part of safe long-term use for many patients.
• Medication hygiene: store at room temperature and protect from moisture as directed on the label.

Alternative options

Depending on your specific diagnosis, disease severity, and response to mesalazine, options may include other formulations or medicines. Below are common alternatives used in ulcerative colitis.

Other mesalazine options

• Different mesalazine formulations: e.g., other modified-release or delayed-release products.
• Rectal mesalazine: suppositories or enemas may be used for inflammation in the rectum/lower colon (if appropriate for your case).

Other IBD medicine classes

• Corticosteroids for short-term control in some flares (specialist-led).
• Immunomodulators (e.g., azathioprine/mercaptopurine) for more difficult disease patterns.
• Biologic medicines for moderate to severe disease or when other treatments fail (specialist-led).

Selection depends on your symptoms, colon involvement, previous response, and safety profile. Your healthcare team can discuss suitable options if Pentasa is not effective or not tolerated.

Market and legal context in the United Kingdom

In the UK, medicines containing mesalazine are regulated under medicines legislation and are supplied according to national guidance. Pentasa is an established treatment in inflammatory bowel disease and is widely available through authorised UK supply channels.

UK practice typically follows evidence-based guidance from bodies such as the NICE (National Institute for Health and Care Excellence) and specialist gastroenterology standards, alongside local hospital/IBD service protocols.

Always check: the product’s status and instructions on the specific site and packaging you receive. If you have questions about suitability, speak with a pharmacist.

Recent guidance — what matters for patients

IBD management guidelines in the UK generally emphasise:

• Using aminosalicylates (such as mesalazine) for appropriate ulcerative colitis activity and maintenance.
• Individualising treatment based on disease extent (e.g., rectal vs left-sided vs extensive colitis) and severity.
• Monitoring safety, especially kidney function and signs of intolerance.
• Reviewing response at sensible intervals and adjusting therapy if targets are not met.
• Optimising adherence and addressing practical barriers (tolerability, timing, formulation) early.

Guidance can be updated. If you’re unsure whether your current plan matches the latest approach, ask your IBD team during routine review.

Delivery and availability (UK)

Availability of Pentasa can vary by strength and formulation. Online pharmacy suppliers typically aim to keep popular packs in stock, but there may be occasional shortages.

What you can expect

• Pack delivery: dispatched in secure packaging suitable for medicines.
• Estimated delivery times: shown at checkout by the online pharmacy provider.
• Stock checks: some pharmacies may show “in stock” versus “limited availability” status.
• Substitution: if an item is unavailable, suppliers may offer alternatives only where allowed and appropriate. Always verify the active ingredient and formulation.

To avoid delays, ensure your delivery address details are correct and you’re available to receive the parcel.

FAQ — Pentasa (mesalazine)

When to seek medical help urgently

Contact urgent care or seek medical advice promptly if you experience:

• Breathing difficulties, swelling of the face/lips, or widespread rash (possible allergy)
• Severe or rapidly worsening abdominal pain, significant worsening of bleeding, or persistent high fever
• Signs of kidney trouble such as reduced urine output, severe swelling, or unexplained marked fatigue
• Severe diarrhoea or dehydration symptoms (especially if you feel faint)